What you just posted is not true according to the clarification that is posted on the Lans website, the LAHO shareholders get nothing unless Lans management decides to give them something after they decide to convert the MSSV shares to common shares, see below:
Clarification of Transaction With Meso Numismatics Inc.
As part of the overall transaction between Lans Holdings Inc. (Lans) and Meso Numismatics Inc. (MSSV)
1. MSSV assumed Lans Debt
2. MSSV assumed the LOI with Global Stem Cells Group
3. Lans received 1,000 series CC redeemable preferred shares of MSSV whereby the 1,000
shares together are convertible into a number of common shares of MSSV equal to the total number of shares outstanding of MSSV at time of conversion multiplied by 0.8, see equation below:
CC: 1,000 MSSV series CC preferred shares
SO: Total common shares outstanding of MSSV at time of CC conversion CS: Number of common shares of MSSV issued from CC conversion
CS = SO x 0.8
Management’s intent is for Lans Holdings to retain the series CC preferred shares and not to immediately convert them into MSSV common shares at this point in time in order for Lans and therefore its shareholders to benefit from any potential future appreciation of MSSV. It is management’s opinion that MSSV, through the acquisition of Global Stem Cells Group, has the potential to create significant value for Lans and its shareholders via the series CC preferred shares stake of MSSV held by Lans. In the event that MSSV gains in value, then that value should be translated onto the preferred series CC shares held by Lans and therefore to Lans and its shareholders as well. At a future date for example, when management deems it appropriate to convert the series CC preferred shares into common shares of MSSV, management may sell these common shares for cash in order to fund Lans operations or distribute these common shares to Lans shareholders, again depending on what management believes would create the most value for Lans and its shareholders. In the event for example where management decided to sell the MSSV common shares to fund Lans operations, then management would seek to apply for a relisting of Lans shares. Management will base its decision on what would bring the most value to the company and therefore its shareholders. Management may redeem a portion of the series CC preferred shares at an earlier date for cash to be used by Lans for working capital as it works to create value for the company and its shareholders.
Management believes that this transaction with MSSV should prove to be beneficial for Lans and its shareholders over time and is confident in the potential value that Global Stem Cells Group (GSCG) could bring. Management believes that GSCG is very well positioned with its numerous offices all over the world to benefit from the significant growth of the worldwide Stem cell industry. In management’s opinion, GSCG has done a good job of aligning itself with reputable medical professionals around the world and has a unique approach to growth and expansion in the industry using its subsidiaries that provide education, certification, equipment, reagents and branding to clinics and medical offices all over the world who desire to enter into the vast and growing stem cell and regenerative medicine industry.
Please refer to this section of Lans website for any further communications that may be posted from time to time by the company.
777 Brickell Avenue, Suite 500 Miami, Florida 33131 | contact@lans.holdings
